Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells

Nucleic Acids Research

Volumn 42, Issue 5, 2014, Pages 3207-3217

  Lehto, Taavi ^a   Alvarez, Alejandra Castillo ^a,b   Gauck, Sarah ^b,c   Gait, Michael J ^d   Coursindel, Thibault ^d,f   Wood, Matthew J A ^e   Lebleu, Bernard ^a   Boisguerin, Prisca ^a,b  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITY OF POTSDAM   (Germany)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f GENEPEP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; PIP6A PMO; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; CELL LINE; CELL MIGRATION; CELL NUCLEUS; CELL STRAIN H2K MDX; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENDOCYTOSIS; EXON SKIPPING; HEART MUSCLE CELL; MOUSE; MUSCLE CELL; MYOBLAST; MYOTUBE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

ANIMALS; CELL-PENETRATING PEPTIDES; CELLS, CULTURED; ENDOCYTOSIS; EXONS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MORPHOLINOS; MUSCLE FIBERS, SKELETAL; MYOBLASTS, SKELETAL; MYOCYTES, CARDIAC; PEPTIDES; RNA SPLICING;

EID: 84898967379     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkt1220     Document Type: Article

References (37)

1. Fairclough, R.J., Wood, M.J. and Davies, K.E. (2013) Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat. Rev. Genet., 14, 373-378.
2. Foster, H., Popplewell, L. and Dickson, G. (2012) Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum. Gene Ther., 23, 676-687.
3. Verhaart, I.E.C. and Aartsma-Rus, A. (2012) Gene therapy for Duchenne muscular dystrophy. Curr. Opin. Neurol., 25, 588-596.
4. Alter, J., Lou, F., Rabinowitz, A., Yin, H.F., Rosenfeld, J., Wilton, S.D., Partridge, T.A. and Lu, Q.L. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med., 12, 175-177.
5. Dickson, G., Hill, V. and Graham, I.R. (2002) Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul. Disord., 12, S67-S70.
6. Dunckley, M.G., Manoharan, M., Villiet, P., Eperon, I.C. and Dickson, G. (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet., 7, 1083-1090.
7. Wilton, S.D., Lloyd, F., Carville, K., Fletcher, S., Honeyman, K., Agrawal, S. and Kole, R. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul. Disord., 9, 330-338.
8. Bremmer-Bout, M., Aartsma-Rus, A., de Meijer, E.J., Kaman, W.E., Janson, A.A., Vossen, R.H., van Ommen, G.J., den Dunnen, J.T. and van Deutekom, J.C. (2004) Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol. Ther., 10, 232-240.
9. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A. and Wilton, S.D. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med., 9, 1009-1014.
10. Yokota, T., Lu, Q.L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S. and Hoffman, E. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol., 65, 667-676.
11. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platenburg, G.J., Sipkens, J.A. et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med., 364, 1513-1522.
12. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med., 357, 2677-2686.
13. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, doseescalation study. Lancet, 378, 595-605.
14. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-ofconcept study. Lancet Neurol., 8, 918-928.
15. Lu, Q.L., Rabinowitz, A., Chen, Y.C., Yokota, T., Yin, H.F., Alter, J., Jadoon, A., Bou-Gharios, G. and Partridge, T. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA, 102, 198-203.
16. Malerba, A., Sharp, P.S., Graham, I.R., Arechavala-Gomeza, V., Foster, K., Muntoni, F., Wells, D.J. and Dickson, G. (2011) Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol. Ther., 19, 345-354.
17. Malerba, A., Thorogood, F.C., Dickson, G. and Graham, I.R. (2009) Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum. Gene Ther., 20, 955-965.
18. Betts, C.A. and Wood, M.J. (2013) Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Curr. Pharm. Des., 19, 2948-2962.
19. El Andaloussi, S.A., Hammond, S.M., Mager, I. and Wood, M.J. (2012) Use of cell-penetrating-peptides in oligonucleotide splice switching therapy. Curr. Gene Ther., 12, 161-178.
20. Goyenvalle, A., Babbs, A., Powell, D., Kole, R., Fletcher, S., Wilton, S.D. and Davies, K.E. (2010) Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol. Ther., 18, 198-205.
21. Moulton, H.M., Fletcher, S., Neuman, B.W., McClorey, G., Stein, D.A., Abes, S., Wilton, S.D., Buchmeier, M.J., Lebleu, B. and Iversen, P.L. (2007) Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem. Soc. Trans., 35, 826-828.
22. Jearawiriyapaisarn, N., Moulton, H.M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P.L. and Kole, R. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther., 16, 1624-1629.
23. Wu, R.P., Youngblood, D.S., Hassinger, J.N., Lovejoy, C.E., Nelson, M.H., Iversen, P.L. and Moulton, H.M. (2007) Cellpenetrating peptides as transporters for morpholino oligomers: Effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res., 35, 5182-5191. (Pubitemid 47394201
24. Wu, B., Moulton, H.M., Iversen, P.L., Jiang, J.G., Li, J., Li, J.B., Spurney, C.F., Sali, A., Guerron, A.D., Nagaraju, K. et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA, 105, 14814-14819.
25. Abes, S., Turner, J.J., Ivanova, G.D., Owen, D., Williams, D., Arzumanov, A., Clair, P., Gait, M.J. and Lebleu, B. (2007) Efficient splicing correction by PNA conjugation to an R-6-Penetratin delivery peptide. Nucleic Acids Res., 35, 4495-4502. (Pubitemid 47244600
26. Ivanova, G.D., Arzumanov, A., Abes, R., Yin, H., Wood, M.J., Lebleu, B. and Gait, M.J. (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res., 36, 6418-6428.
27. Yin, H., Saleh, A.F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M.J. et al. (2011) Pip5 transduction peptides direct high efficiency oligonucleotidemediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther., 19, 1295-1303.
28. Betts, C., Saleh, A.F., Arzumanov, A.A., Hammond, S.M., Godfrey, C., Coursindel, T., Gait, M.J. and Wood, M.J. (2012) Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids, 1, e38.
29. Wu, B., Lu, P., Benrashid, E., Malik, S., Ashar, J., Doran, T.J. and Lu, Q.L. (2010) Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther., 17, 132-140.
30. Davies, K.E. and Nowak, K.J. (2006) Molecular mechanisms of muscular dystrophies: Old and new players. Nat. Rev. Mol. Cell Biol., 7, 762-773.
31. Barrere-Lemaire, S., Combes, N., Sportouch-Dukhan, C., Richard, S., Nargeot, J. and Piot, C. (2005) Morphine mimics the antiapoptotic effect of preconditioning via an Ins(1, 4, 5)P3 signaling pathway in rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol., 288, H83-H88.
32. Sadoshima, J. and Izumo, S. (1993) Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ. Res., 73, 424-438.
33. Said Hassane, F., Saleh, A.F., Abes, R., Gait, M.J. and Lebleu, B. (2010) Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci., 67, 715-726.
34. Lehto, T., Kurrikoff, K. and Langel, U. (2012) Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv., 9, 823-836.
35. Cleal, K., He, L., Watson, P.D. and Jones, A.T. (2013) Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles. Curr. Pharm. Des., 19, 2878-2894.
36. Wang, Q., Yin, H., Camelliti, P., Betts, C., Moulton, H., Lee, H., Saleh, A.F., Gait, M.J. and Wood, M.J. (2010) In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J. Gene Med., 12, 354-364.
37. Piot, C., Lemaire, S., Albat, B., Seguin, J., Nargeot, J. and Richard, S. (1996) High frequency-induced upregulation of human cardiac calcium currents. Circulation, 93, 120-128. (Pubitemid 26006578